ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Oral versus Intravenous Mycophenolate Mofetil Administration: A Single Center Experience on Incidence of Acute Kidney Injury

P. Chung1, K. Forrester2, S. Ganesh1

1Division of Pulmonary Critical and Sleep Medicine, University of Southern California, Los Angeles, CA, 2Department of Clinical Pharmacy, University of Southern California School of Pharmacy, Los Angeles, CA

Meeting: 2020 American Transplant Congress

Abstract number: B-295

Keywords: Immunosuppression, Lung transplantation, Mycophenolate mofetil, Renal injury

Session Information

Session Name: Poster Session B: Lung: All Topics

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: Mycophenolate mofetil (MMF) is one of the main immunosuppressive medications given in lung transplantation (LTx). It is given orally (PO) or intravenously (IV). In heart transplantation patients, similar pharmacokinetics and bioavailability have been reported in either route of administration, but no data exists for LTx. Based on our center’s experience, we suspected a higher incidence of acute kidney injury (AKI) with IV MMF when patients were unable to receive medications orally. This study examines the incidence of AKI in LTx patients who received either oral or IV MMF perioperatively.

*Methods: This study is a single center (Keck Medical Center at University of Southern California), retrospective chart review comparing the incidence of AKI among LTx patients who received oral or IV MMF. Review period was from January 2017 to December 2019. Renal functions immediately pre- and post-transplantation were reviewed. The incidence of AKI was defined by the Kidney Disease Improving Global Outcome (KDIGO) guidelines.

*Results: During the review period, a total of 54 patients underwent LTx. Among them, 25 patients received oral MMF, and 29 patients received IV MMF. The average serum creatinine (SCr) level increased by 0.02mg/dL in the oral group and by 0.04mg/dL in the IV group. AKI was noted in 6 patients in the oral group and 13 patients in the IV group (24% vs. 45%). However, the oral group with AKI had a higher increase in absolute SCr values compared to IV group with AKI (0.25mg/dL vs. 0.18mg/dL).

*Conclusions: There is lack of data and guidelines for optimal route of MMF administration in LTx patients. While there are multiple confounding factors such as duration on cardiopulmonary bypass machine, hemodynamics, degree of blood loss, number of received blood products, and other nephrotoxic medications that affect renal function, only the route of administration was examined in this study. The incidence of AKI was almost twice as much in the IV group compared to the oral group. However, AKI was more severe in the oral group based on absolute values of increased SCr levels. We propose the possibility of different effect of oral vs. IV MMF on renal function perioperatively. The number of patients in this study is small, but the observation and trend reported here should lead to further studies examining the optimal MMF administration route as it may affect the pharmacokinetics and bioavailability of immunosuppression as well as LTx outcome.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Chung P, Forrester K, Ganesh S. Oral versus Intravenous Mycophenolate Mofetil Administration: A Single Center Experience on Incidence of Acute Kidney Injury [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/oral-versus-intravenous-mycophenolate-mofetil-administration-a-single-center-experience-on-incidence-of-acute-kidney-injury/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences